The article “Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke” reports on a randomized controlled trial investigating the use of autologous MSCs in chronic ischemic stroke patients. The study found no significant improvement in the primary outcome (modified Rankin Scale score at 3 months). However, secondary analyses indicated significant improvements in lower extremity motor function in the MSC group, especially in patients with low predicted recovery potential. No serious treatment-related adverse events were observed, suggesting the treatment is feasible and safe.